Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 8/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | MMP2 | P08253 | 3/20 | 0.44 |
| ▸ | MMP9 | P14780 | 3/20 | 0.44 |
| ▸ | MMP8 | P22894 | 3/20 | 0.44 |
| ▸ | MMP12 | P39900 | 3/20 | 0.44 |
| ▸ | MMP14 | P50281 | 3/20 | 0.44 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.42 |
| ▸ | DHODH | Q02127 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | ATM | Q13315 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4651379 | 0.90 | ALDH1A1 (0.58) | PTPN1ALDH1A1LMNA | |
| SCHEMBL7054363 | 0.90 | PTPN1 (0.46) | PTPN1ALDH1A1MMP2MMP9LMNA | |
| Benzene SCHEMBL4650214 | 0.90 | PTPN1 (0.53) | PTPN1ALDH1A1S1PR3DHODHLMNA | |
| SCHEMBL4651105 | 0.90 | PTPN1 (0.44) | PTPN1ALDH1A1MMP2MMP9LMNA | |
| SCHEMBL4650271 | 0.88 | BDKRB1 (0.45) | PTPN1ALDH1A1MMP2MMP9MMP8 | |
| SCHEMBL4651111 | 0.88 | ALDH1A1 (0.41) | PTPN1ALDH1A1LMNAATML3MBTL1 | |
| SCHEMBL4650872 | 0.88 | ALDH1A1 (0.60) | PTPN1ALDH1A1 | |
| SCHEMBL7050019 | 0.86 | ALDH1A1 (0.54) | PTPN1ALDH1A1 | |
| SCHEMBL4651316 | 0.82 | ALDH1A1 (0.48) | PTPN1ALDH1A1MMP2MMP9LMNA | |
| SCHEMBL4650322 | 0.81 | ALDH1A1 (0.48) | ALDH1A1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6586467-B2 | Tyrosine phosphatase inhibitors useful in the treatment or prevention of Type II Diabetes Mellitus | ARRAY BIOPHARMA INC. | 2003-07-01 | — | — | US | claimed |
| US-20020040003-A1 | Preparation of phosphatase inhibitors | ARRAY BIOPHARMA INC. | 2002-04-04 | — | — | US | claimed |
| EP-1301474-B1 | TYROSINE DERIVATIVES AS PHOSPHATASE INHIBITORS | ARRAY BIOPHARMA INC (US) | 2008-09-10 | — | — | EP | disclosed |
| US-6586467-B2 | Tyrosine phosphatase inhibitors useful in the treatment or prevention of Type II Diabetes Mellitus | ARRAY BIOPHARMA INC. | 2003-07-01 | — | — | US | disclosed |
| US-20020040003-A1 | Preparation of phosphatase inhibitors | ARRAY BIOPHARMA INC. | 2002-04-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020040003-A1 | Preparation of phosphatase inhibitors | PTPRS, PTPRO, PTPRR | PTPN1 5/4885ALDH1A1 446/4885MMP2 1609/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.